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Abstract
Background: To analyze the rate of larynx preservation in patients of locally advanced hypopharyngeal cancer treated 
with intensity modulated radiotherapy (IMRT) plus concurrent chemotherapy, and compare the results with patients 
treated with primary surgery.
Methods: Between January 2003 and November 2007, 14 patients were treated with primary surgery and 33 patients 
were treated with concurrent chemoradiotherapy (CCRT) using IMRT technique. Survival rate, larynx preservation rate 
were calculated with the Kaplan-Meier method. Multivariate analysis was conducted for significant prognostic factors 
with Cox-regression method.
Results: The median follow-up was 19.4 months for all patients, and 25.8 months for those alive. The 5-year overall 
survival rate was 33% and 44% for primary surgery and definitive CCRT, respectively (p = 0.788). The 5-year functional 
larynx-preservation survival after IMRT was 40%. Acute toxicities were common, but usually tolerable. The rates of 
treatment-related mucositis (≥ grade 2) and pharyngitis (≥ grade 3) were higher in the CCRT group. For multivariate 
analysis, treatment response and cricoid cartilage invasion strongly correlated with survival.
Conclusions: IMRT plus concurrent chemotherapy may preserve the larynx without compromising survival. Further 
studies on new effective therapeutic agents are essential.
Background
Laryngopharyngectomy followed by radiotherapy (RT)/
chemoradiotherapy (CRT) has been one of treatment
modalities for patients with hypopharyngeal cancer.
However, it leads to the loss of a functional larynx. Lar-
ynx preservation modality for hypopharyngeal cancer has
been tested in a trial conducted by the European Organi-
zation for Research and Treatment of Cancer (EORTC)
Head and Neck Cancer Cooperative group [1]. It con-
cludes that induction chemotherapy plus definitive RT
offered 35% of 5-year larynx preservation rate and does
not compromise survival compared with surgery. Some
retrospective studies show a 5-year overall survival vary-
ing widely from 14% to 43% after RT [2-4]. However, the
actual larynx preservation rate is seldom reported. Con-
current chemoradiotherapy (CCRT) has been thought to
be better than sequential treatment from previous stud-
ies. Two important meta-analyses have concluded that
the survival benefit from chemotherapy in head and neck
cancer is based on concurrent, rather than induction use
[5,6]. Nevertheless, there has been no randomized trial
testing definitive CCRT versus surgery for hypopharyn-
geal cancer so far.
Intensity modulated radiotherapy (IMRT), a new RT
technique, has the advantages of precise delivery, target
conformity and normal tissue sparing. It is able to achieve
a very high rate of locoregional control with less morbid-
ity under optimal target delineation, appropriate physical
quality control and accurate patient setup [7]. Although it
has provided promising results in patients with other
subsites of head-and-neck cancer [7-13], publications of
using IMRT on hypopharyngeal cancer are rare. In our
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institution, CCRT has been one of the choices for resect-
able advanced hypopharyngeal cancer for more than 10
years and IMRT has been introduced since 2003. In this
study, we analyze the rate of larynx preservation in
patients of advanced resectable hypopharyngeal cancer
after IMRT plus concurrent chemotherapy and compare
the result with primary surgery.
Methods
Patients
We retrospectively reviewed medical records from Janu-
ary 2003 to November 2007 and identified 47 patients
with histologically confirmed, previously untreated,
locally advanced resectable squamous cell carcinoma of
hypopharynx, who underwent primary surgery or defini-
tive IMRT with concurrent platinum-based chemother-
apy. Locally advanced resectable disease was defined as
AJCC 2002 clinical stage II-IVA, excluding T1N0, small
T2N0, T4b, N3, and M1 disease. Patients with T1-2N0
disease were excluded because they already had conspic-
uous success on larynx preservation using RT alone or
CCRT, and rarely needed radical surgery. Those patients
who had second primary cancer were excluded, too. The
median age at diagnosis was 57, ranging from 40 to 73.
Pretreatment evaluation included medical history, physi-
cal examination, complete blood counts, serum biochem-
istries, laryngoscopy, upper GI panendoscopy, chest X-
ray, head and neck MRI and/or CT. Bone scan was con-
ducted according to the clinical symptoms. Positron
Emission Tomography was not routinely used for staging
purpose. The information of advantages and disadvan-
tages of different treatments were offered to all patients.
The final treatment modalities depended on the patients'
decision except for 3 patients who were assigned to
CCRT; 1 with poor performance status (ECOG = 2) and 2
with severe medical comorbidity who could not undergo
surgery under general anesthesia. The detailed patient
characteristics were listed in Table 1.
Surgery
Fourteen patients underwent radical surgery as the pri-
mary treatment. These included 11 patients who had
total laryngectomy with partial pharyngectomy and 3
patients who underwent total laryngectomy with total
pharyngectomy. Ipsilateral thyroid lobectomy was con-
ducted in 2 patients due to suspected thyroid gland
involvement. All 14 patients also had neck dissection and
3 of them underwent bilateral neck dissection. The type
of neck dissection was determined by the clinical nodal
status individually. The general principle was ipsilateral
modified radical neck dissection or supraomohyoid neck
dissection for clinical N0 disease, ipsilateral modified
radical neck dissection or extended neck dissection for
Table 1: Patient characteristics.
Treatment
Surgery CCRT p-value
No.(%) No.(%)
No. of patients 14(30) 33(70)
Sex male 13(93) 32(97) 0.523
female 1(7) 1(3)
Age(y) ≥ 60 7(50) 14(42) 0.633
< 60 7(50) 19(58)
Median 58 57
Range 43-73 40-71
Performance 
(ECOG)
01 0 2 3 0 . 8 0 5
14 9
20 1
Location Pyriform sinus 11(79) 30(91) 0.085
Pharyngeal wall 0(0) 2(6)
Post-cricoid 3(21) 1(3)
Histology grade 1-2 8(57) 20(61) 0.292
3 6(43) 9(27)
NA 0(0) 4(12)
cT 1 0 1(3) 0.795
2 3(21) 7(21)
3 4(29) 6(18)
4a 7(50) 19(58)
cN 0 5(36) 9(27) 0.488
1 1(7) 7(21)
2a-2c 8(57) 17(52)
Clinical stage II 2(14) 2(6) 0.652
III 2(14) 5(15)
IVA 10(71) 26(79)
cTCI Yes 7(50) 19(58) 0.633
No 7(50) 14(42)
cCCI Yes 2(14) 7(21) 0.581
No 12(86) 26(79)
RT dose(Gy) Median 62 70
Range 60-70 70-75
Follow-up 
time(m)
Median 19.8 18.8
Range 6.7-67.9 1.9-72.3
Abbreviation: CCRT, concurrent chemoradiotherapy; ECOG, Eastern 
Cooperative Oncology Group; NA, not available; cT, clinical T stage; 
cN, clinical N stage; cTCI, clinical thyroid cartilage invasion; cCCI, 
clinical cricoid cartilage invasionHuang et al. Radiation Oncology 2010, 5:37
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clinically positive-node disease. There were 21 nodes dis-
sected on average. Pathological stages were identical to
clinical stages in 10 patients. Another 4 patients had
higher pathological stages than clinical stages.
Radiotherapy technique
All patients were immobilized in supine position using
custom-made thermoplastic masks. CT simulation was
conducted with 3-mm slice thickness (SIEMENS Sim-
view NT simulator). All patients in CCRT group were
treated with IMRT technique. Inverse treatment planning
was performed using the Plato RTS computer system ver-
sion 2.6.3 (Nucletron). There were usually 6 or 7 beams
with a single isocenter. The gross tumor volume (GTV)
was defined as grossly visible primary tumor and meta-
static lymphadenopathy on image or physical examina-
tion. The high-risk clinical target volume (CTV2)
encompassed the GTV, the pyriform sinus, post-cricoid
area, retropharyngeal, parapharyngeal region and bilat-
eral level II-III nodal area. The ipsilateral level IB and V
were included if clinical nodal disease was present. Four
patients underwent tracheostomy before RT to prevent
airway obstruction; their tracheostoma sites were
included in the CTV2. The low-risk clinical target vol-
ume (CTV3) included bilateral level IV and supraclavicu-
lar areas. The planning target volume 1 (PTV1) was GTV
plus a 0.6-cm margin. The PTV2, PTV3 was CTV2,
CTV3 plus a 0.4-cm margin, respectively. The median
prescribed dose to the PTV1, PTV2, PTV3 was 70, 60, 50
Gy, respectively. In the primary surgery group, 10
patients had postoperative CCRT or RT alone. For post-
operative IMRT, the median prescribed dose to the high-
risk and low-risk area was 62 and 50 Gy, respectively. The
daily fraction dose to the PTV1 was 1.8-2.0 Gy, five frac-
tions a week. All the PTVs were treated at the same time
using simultaneous integrated boost (SIB) technique. The
mean dose to the parotid glands was 26 Gy or lower if
p o s s i b l e  t o  r e d u c e  d a m a g e  t o  s a l i v a r y  f u n c t i o n s .  T h e
maximal dose of the spinal cord was kept below 45 Gy. A
pair of orthogonal radiographs or images taken from
Elekta electronic portal imaging device were obtained to
confirm positioning accuracy before the first day of treat-
ment. Radiotherapy was delivered with 6 MV photons
from a linear accelerator (Precise, Elekta).
Chemotherapy
Chemotherapy included cisplatin +/- 5-fluorouracil. In
the CCRT arm, 15 patients had cisplatin weekly (30 mg/
m2) for up to 8 cycles or tri-weekly (60-80 mg/m2) for 3
cycles. Eighteen patients had cisplatin (60-80 mg/m2 day
1) + 5-fluorouracil (800-1000 mg/m2 day 1 to 4) every 3 to
4 weeks. The first cycle of chemotherapy was often given
in the same week as the beginning of RT. Seven patients
in the primary surgery group underwent adjuvant CCRT;
4 with cisplatin alone and 3 with cisplatin + 5-fluoroura-
cil. The protocol of chemotherapy was adjusted by the
medical oncologist according to the toxicity and patients'
tolerance.
Patient follow-up and toxicity evaluation
All patients were examined weekly by laryngoscopy and
physical examination during RT. Treatment response and
toxicity were recorded by the radiation oncologist. After
treatment, they were followed by both radiation oncolo-
gists and head & neck surgeons 1-2 months for the first 6
months, and then every 3 months for 2 years, then every
4-6 months. History taking, physical examination, serum
biochemistry, treatment-related toxicity evaluation, CT
or MRI of head and neck and laryngoscopy were per-
formed in the follow-up. The toxicity grading was based
on Common Toxicity Criteria for Adverse Events
(CTCAE) v3.0. Treatment response was assessed by the
radiation oncologists and head and neck surgeons at 1
month after completion of RT according to the finding of
laryngoscopy, CT or MRI, and physical examination.
Biopsy or PET was conducted for the patients whose
response grading was in controversy. Complete response
(CR) was defined as complete disappearance of all
lesions; Partial response (PR) was at least 50% decrease in
dimension; Progressive disease (PD) was 25% increase;
Stable disease (SD) was neither PR nor PD. Laryngec-
tomy-free survival referred to patients who survived at
the last follow-up without laryngectomy, regardless of
hypopharynx-larynx function. Functional larynx-preser-
vation survival was defined as survival with preservation
of not only an intact hypopharynx-larynx, but also nor-
mal function. Larynx preservation rate was the rate of
patients who never underwent laryngectomy, regardless
of survival or functional preservation.
Statistics
Overall survival, locoregional progression-free survival,
larynx-preservation survival rates were calculated with
the Kaplan-Meier method, and the differences between
groups in survival curves were examined using the log-
rank test. All of the tests were two-sided, and p < 0.05 was
considered to be statistically significant. The differences
of the patient characteristics between the 2 groups were
examined with Chi-square test. Multivariate analysis was
conducted for significant prognostic factors with Cox-
regression method. Analysis of the data was performed
using SPSS 12 software.
Results
Survival
The median follow-up was 19.4 months for all patients,
19.8 months for surgery group and 18.8 months for
CCRT group, respectively. In those alive, the median fol-Huang et al. Radiation Oncology 2010, 5:37
http://www.ro-journal.com/content/5/1/37
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low-up time was 25.8 months, ranging from 14.2 to 72.3
months. At the time of analysis, 23 patients were alive, 2
patients were lost to follow-up, and 22 patients had died;
20 died of disease, 1 died of heart attack, 1 died of esoph-
ageal cancer. The 2-year and 5-year overall survival of all
patients was 57% and 37%, respectively. The 5-year over-
all survival rate was 33% and 44% for primary surgery and
definitive CCRT, respectively (p = 0.788, Figure 1).
The 5-year disease-specific survival rate of primary
surgery and CCRT group was 33% and 56%, respectively
(p = 0.970). The 5-year disease-free survival was 25% and
41%, respectively (p = 0.844). The 5-year locoregional
progression-free survival was 15% and 53%, respectively
(p = 0.365). Differences were not statistically significant.
Loco-regional progression was the main cause of failure
in both groups. The detailed patterns of failure were
shown in Table. 2. Eleven patients had neck failure; 8 in
the ipsilateral neck, 2 in the contralateral neck, and 1 in
the tracheostoma site. All were in-field failure in the
PTV2.
Larynx preservation
After definitive CCRT, the number of patients with CR,
PR, SD, and PD was 16 (48%), 15 (45%), 1 (3%), and 1
(3%), respectively. Six patients underwent salvage surgery
(1 neck dissection, 5 laryngectomy with neck dissection).
One of them had pathological CR. One patient who com-
pleted CCRT had local recurrence and ultimately
required tracheostomy. One additional patient with fixa-
tion of his hemilarynx at diagnosis experienced bilateral
vocal cord palsy 1 month after completion of RT. He sub-
sequently needed tracheostomy. Eventually, 22 patients
preserved a functional larynx. Figure 2 showed the func-
tional larynx-preservation survival of the patients in
CCRT group. The 5-year functional larynx-preservation
survival, laryngectomy-free survival rate was 40%, 43%,
respectively.
Prognostic factor analysis
The result of univariate analysis of survival was shown in
Table 3. Clinical T stage, thyroid cartilage invasion, cri-
coid cartilage invasion, worse performance status and
treatment response significantly affected overall survival.
For multivariate analysis, these 5 factors were included
for evaluation of their effects on overall survival (Table
4.). Free of cricoid cartilage invasion and CR after treat-
ment were significant predictors for better overall sur-
vival (p = 0.043 and < 0.001, respectively).
Treatment response was the most important prognos-
tic factor. In CCRT group, the 16 patients with CR had
75% 5-year overall survival, which was significantly better
than non-CR patients. All non-CR patients who did not
undergo salvage laryngectomy eventually died within 2
years. Five patients who underwent salvage laryngectomy
had a 2-year survival rate of 40%.
Toxicity
A c u t e  a n d  l a t e  t o x i c i t i e s  w e r e  l i s t e d  i n  T a b l e  5 .  A c u t e
pharyngitis was the most common sequela and developed
in virtually all of the patients. The rates of mucositis (≥
grade 2) and pharyngitis (≥ grade 3) were higher in the
CCRT group. Since both groups used the same fraction-
ation dose, this was probably due to the higher total radi-
ation dose in the CCRT group (70-75 Gy vs. 60-70 Gy).
Three patients in the CCRT group suffered from grade 4
leukopenia. There were 4 patients who had RT interrup-
tion more than 5 days due to toxicities (3 grade 3 leuko-
penia, 1 grade 3 pharyngitis). In general, CCRT was
tolerable for most patients.
Two patients had severe late toxicities and ultimately
failed to retain a functional larynx in the CCRT group.
One needed tracheostomy because of bilateral vocal cord
palsy. The other became feeding tube-dependent after
salvage laryngectomy. Xerostomia was mild and contin-
ued to decrease over time from the end of RT. Only one
patient complained of grade 2 xerostomia at 1 year after
treatment. Her average dose of the bilateral parotid
glands was 25.9 and 23.1 Gy.
Previous CCRT did not increase perioperative compli-
cation rate in the subsequent salvage surgery. For the six
patients who underwent salvage surgery, 2 experienced
surgery-related complications (1 with pharyngocutane-
ous fistula, 1 with wound infection). This complication
rate was comparable to that of the primary surgery group.
However, one patient who had T4aN1M0 disease and sal-
vage pharyngolaryngoesophagectomy developed a
Figure 1 Overall survival of the primary surgery group vs. concur-
rent chemoradiotherapy (CCRT) group. The 5-year overall survival 
rate was 33% and 44% for primary surgery and definitive CCRT, respec-
tively (p = 0.788).
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carotid artery rupture 4 months after surgery. He was res-
cued by an emergent ligation operation. He was still alive
with no evidence of disease at the last follow-up.
Discussion
Our study shows that IMRT with concurrent chemother-
apy demonstrated comparable results with primary sur-
gery in terms of overall survival, disease-specific survival,
and local control. The biggest reward is that it provides a
40% 5-year larynx preservation survival rate. Table 6
shows the retrospective treatment results including lar-
ynx preservation rate in the literature of hypopharyngeal
cancer after CCRT with IMRT technique [14,15].
Although CCRT is more effective for advanced head
and neck cancer than RT alone, it may also be more toxic
[5,16]. IMRT may spare more normal tissues, and has
been shown to have decreased toxicities in head and neck
cancer [17-19]. In the present study, IMRT with concur-
rent chemotherapy is tolerable although there are more
severe mucositis and pharyngitis. The interruption of RT
due to toxicities is not common. It seems that the advan-
tage of IMRT offsets the disadvantage of CCRT.
We recommend that all potential candidates of larynx
preservation should be discussed in a multidisciplinary
team to assess the justification, advantages and disadvan-
tages. Besides, optimal delineation of target volume is a
requirement. Our design of the PTV described in section
"Methods, Radiation technique" is relatively small. How-
ever, there has been no out-field failure in the neck. Our
Table 2: Patterns of failure after treatment
Failure Primary surgery
No.(%)
Definitive CCRT
No.(%)
Total
No.(%)
p-value
None 3(21) 17(52) 20(43) 0.056
LR alone 6(43) 11(33) 17(36) 0.534
Distant alone 1(7) 2(6) 10(6) 0.890
LR & distant 4(29) 3(9) 7(15) 0.086
Second cancer 1(7) 5(15) 6(13) 0.452
Abbreviation: No., number; LR, loco-regional; CCRT, concurrent chemoradiotherapy
Figure 2 Functional larynx-preservation survival after concur-
rent chemoradiotherapy. Four patients underwent tracheostomy at 
initial diagnosis to prevent airway obstruction. The 5-year functional 
larynx-preservation survival was 40%.
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Table 3: Prognostic factors for overall survival in univariate 
analysis.
Factors p-value
All patients CCRT
Age ≥60 vs. <60 years 0.922 0.942
Histology Grade 1-2 vs. 3 0.995 0.768
Location Pyriform sinus vs. Pharyngeal wall 
vs. Post-cricoid
0.396 0.359
Stage II-III. vs. IVA 0.109 0.072
cT stage T1-3 vs. T4a 0.024 0.020
cTCI Yes vs. No 0.037 0.034
cCCI Yes vs. No 0.003 0.010
cN stage N0-2a vs. N2b-2c 0.087 0.051
Performance(ECOG) 0 vs. 1-2 0.025 0.037
Pretreatment hemoglobin ≤13 vs. >13 gm/dl 0.117 0.172
Treatment modality Surgery vs. CCRT 0.788
Total RT day (CCRT group) <60 vs. ≥60 days 0.568
Treatment response CR vs. PR+SD+PD < 0.001 < 0.001
Abbreviation: CCRT, concurrent chemoradiotherapy; cTCI, clinical 
thyroid cartilage invasion; cCCI, clinical cricoid cartilage invasion; 
CR, complete response; PR, partial response; SD, stable disease; 
PD, progressive diseaseHuang et al. Radiation Oncology 2010, 5:37
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guideline for target contouring appears to be reasonable
and may serve as a reference.
Salvage surgery is necessary for non-CR patients. No
non-CR patients who did not have salvage surgery were
cured in this study. Therefore, it is essential to identify
the non-CR patients to CCRT as early as possible. In our
practice, we determined the response after a full dose of
70 Gy. This did not interfere with wound healing after sal-
vage surgery. A randomized study may identify those
po t e n t i a l  p a t i e n t s  f o r  C CR T  a t  a  l o w e r  d o s e  a s  i n  t h e
laryngeal cancer [20].
There are at least two limitations in this study. First, it is
a retrospective study from a single institute. Non-ran-
domization, as well as low sample size, may make selec-
tion bias and comparison statistically inherently
inappropriate. Second, we add a small margin (6 mm
around GTV) to create a PTV, concerning normal tissue
damage. It's helpful to decrease treatment toxicities.
However, this may be one of factors that compromise
locoregional control.
Our IMRT using SIB technique with daily fractionation
dose of 1.8-2 Gy to PTV1 results in approximate 1.5 Gy to
the lower neck per day. This may be criticized for its
probable radiobiological disadvantage. However, there is
no in-field failure in the PTV3 in this study. In other
series using IMRT with SIB in head and neck cancer, the
daily dose to the lower neck is about 1.6 Gy and no higher
failure rate is mentioned either [14]. There are indeed
diverse dose fractionation regimens in practice of IMRT
with SIB technique nowadays [21]. The long-term locore-
gional results in the low-risk area using different proto-
cols are still unknown. A large prospective study with
long-term follow-up is needed for creating standard regi-
mens.
In our study , the patients have a 40% opportunity to
retain their functional larynx which is an invaluable gain
for every patient. This would be very cost-effective com-
pared to the benefits of many cancer treatments that offer
10-20% locoregional control rate [22,23].
Nearly all head and neck cancer expresses EGFR and it
is correlated to an unfavorable prognosis [24-26]. In a
phase III trial, adding cetuximab, an EGFR inhibitor , to
Table 4: Prognostic factors for overall survival in 
multivariate analysis.
Factors 5-year overall 
survival 
(all patients)
p-value
All patients CCRT group
cT stage 0.671 0.376
T1-3 67%
T4a 16%
cTCI 0.815 0.621
No 68%
Yes 16%
cCCI 0.023 0.020
No 57%
Yes 0%
Performance 0.443 0.990
ECOG 0 47%
ECOG 1-2 0%
Treatment response < 0.001 0.001
CR 52%
PR+SD+PD NA*
Abbreviation: CCRT, concurrent chemoradiotherapy; cTCI, 
clinical thyroid cartilage invasion; cCCI, clinical cricoid cartilage 
invasion; CR, complete response; PR, partial response; SD, stable 
disease; PD, progressive disease; NA, not available
*The longest follow-up of this subgroup is 28 months and 2-year 
survival rate is 15%.
Table 5: Treatment toxicities.
Patient number
Surgery CCRT p-value
Patients 14 33
Acute toxicities
Skin (≥Gr. 2) 5 6 0.194
Mucositis (≥Gr. 2) 1 13 0.027
Pharyngitis (≥Gr. 2) 9 29 0.060
Pharyngitis (≥Gr. 3) 0 10 0.020
Leukopenia (≥Gr. 3) 0 5 0.123
Anemia (≥Gr. 2) 1 11 0.060
Weight loss (≥Gr. 2) 4 13 0.480
Wound infection 3 1* 0.039
Pharyngocutaneous fistula 3 1* 0.039
Late toxicities
Xerostomia at 1 yr after treatment 
(≥Gr. 2)
1 0 0.121
Neck fibrosis (≥Gr. 2) 3 3 0.246
Feeding tube-dependent 0 1* 0.510
Dysphagia (≥Gr. 2) 0 2 0.347
Carotid artery blowout 0 1* 0.510
Vocal cord palsy 4
Abbreviation: CCRT, concurrent chemoradiotherapy
*The patients underwent not only CCRT, but also salvage surgery.Huang et al. Radiation Oncology 2010, 5:37
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RT provided improvement in locoregional control and
overall survival on squamous cell carcinoma of the head
and neck [27]. However, only 15% were patients of hypo-
pharyngeal cancer in that study and subgroup analysis
showed no statistical benefit for them. It is being investi-
gated in an ongoing phase III trial (RTOG-0522) compar-
ing CCRT with CCRT plus cetuximab in patients with
stage III or IV squamous cell carcinoma of the orophar-
ynx, hypopharynx, and larynx [28].
Conclusions
Locally advanced resectable hypopharyngeal cancer can
be treated with IMRT plus concurrent chemotherapy,
resulting in a 40% 5-year functional larynx-preservation
survival. This combined modality, although leading to
more mucositis and pharyngitis, is tolerable. However,
the prognosis is still poor. Further studies on new effec-
tive therapeutic agents are essential.
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